Grażyna E. Sroga

Grażyna E. Sroga

Auto-generated profile, based on publicly available information

Grażyna E. Sroga

Rensselaer Polytechnic Institute, NY (RPI), Troy, NY 12180, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2012 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
GSGrażyna E. Sroga
Grażyna E. Sroga
DVDeepak Vashishth
Deepak Vashishth


Verified
Journal Article
Open access
PDF file
Ali El-FarAli El-Far
Ali El-Far
GSGrazyna Sroga
Grazyna Sroga
SASOAD Khalil ALJAOUNI
SOAD Khalil ALJAOUNI
Shaker A MousaShaker A Mousa
Shaker A Mousa
Interactions of the receptor for advanced glycation end product (RAGE) and its ligands in the context of their role in diabetes mellitus, inflammation, and carcinogenesis have been extensively investigated. This review focuses on the role of RAGE-ligands and anti-RAGE drugs capable of controlling cancer progression. Different studies have demonstrated interaction of RAGE with a diverse range of acidic (negatively charged) ligands such as advanced glycation end products (AGEs), high-mobility group box1 (HMGB1), and S100s, and their importance to cancer progression. Some RAGE-ligands displayed effects on anti- and pro-apoptotic proteins through upregulation of the phosphatidylinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), mitogen-activated protein kinases (MAPKs), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), and nuclear factor kappa B (NF-κB) pathways, while downregulating p53 in cancer progression. In addition, RAGE may undergo ligand-driven multimodal dimerization or oligomerization mediated through self-association of some of its subunits. We conclude our review by proposing possible future lines of study that could result in control of cancer progression through RAGE inhibition.